Strategic Deal Between Lundbeck and Longboard Pharmaceuticals Aims to Enrich Neuroscience Pipeline

2 min read | October 14, 2024 03:34 AM PDT | By Team Kalkine Media

Google News:

Strategic Deal Between Lundbeck and Longboard Pharmaceuticals Aims to Enrich Neuroscience Pipeline — Image source: Shutterstock

Recent News

Is Pitney Bowes Still Hiding Value After Its Rally?

What’s Driving Unity Bancorp Climb To New Highs?

Why United Parcel Service Is Back on The Market Radar?

Why Is Halliburton Facing Fresh Market Pressure?

Make Kalkine Media
My Trusted Source

Highlights:

Lundbeck has announced the acquisition of Longboard Pharmaceuticals to strengthen its neuroscience pipeline, valued at approximately USD 2.6 billion.
The deal will integrate the innovative product bexicaserin, currently in late-stage development for Developmental and Epileptic Encephalopathies (DEEs).
Bexicaserin has demonstrated promising anti-seizure effects, with a global phase III trial, DEEp SEA, commencing in September 2024.

Description:

Longboard Pharmaceuticals, {NASDAQ:LBPH} a move designed to enhance its neuroscience pipeline. This acquisition, valued at around USD 2.6 billion in equity and USD 2.5 billion net of cash, will significantly bolster Lundbeck's portfolio with the addition of bexicaserin, an innovative treatment currently in late-stage development for Developmental and Epileptic Encephalopathies (DEEs).

Bexicaserin, which targets 5-HT2C receptors, has shown promising anti-seizure effects in both preclinical and clinical studies. The acquisition comes at a critical time, as the global phase III trial known as DEEp SEA began in September 2024, aiming to evaluate the efficacy and safety of bexicaserin in patients with DEEs. This trial is expected to provide vital data that could lead to significant advancements in treatment options for patients suffering from these challenging neurological conditions.

Lundbeck plans to finance the acquisition using its existing cash resources along with bank financing, reflecting a strong commitment to investing in its future growth. The acquisition has already received approval from the boards of both companies and is anticipated to close in the fourth quarter of 2024, pending regulatory approvals.

This acquisition aligns with Lundbeck's Focused Innovator strategy, which emphasizes developing treatments for neuro-rare conditions with unmet medical needs. By integrating Longboard Pharmaceuticals' innovative offerings, Lundbeck aims to enhance its capabilities in addressing these conditions, positioning the company for potential growth into the next decade. The strategic move underscores Lundbeck’s commitment to expanding its neuroscience portfolio and reinforcing its position as a leader in the field of mental health and neurological disorders.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.